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OBJECTIVE — To examine insulin’s effect on the tissue glucose concentration at the site of
subcutaneous insulin administration.
RESEARCH DESIGN AND METHODS — A CMA-60 microdialysis (MD) catheter and
a 24-gauge microperfusion (MP) catheter were inserted into the subcutaneous adipose tissue of
fasting, healthy subjects (n  5). Both catheters were perfused with regular human insulin (100
units/ml) over a 6-h period and used for glucose sampling and simultaneous administration of
insulinatsequentialratesof0.33,0.66,and1.00units/h(eachratewasusedfor2h).Beforeand
after the insulin delivery period, both catheters were perfused with an insulin-free solution (5%
mannitol) for 2 h and used for glucose sampling only. Blood plasma glucose was clamped at
euglycemic levels during insulin delivery.
RESULTS — Start of insulin delivery with MD and MP catheters resulted in a decline of the
tissue glucose concentration and the tissue-to-plasma glucose ratio (TPR) for 60 min (P 
0.05). However, during the rest of the 6-h period of variable insulin delivery, tissue glucose
concentration paralleled the plasma glucose concentration, and the TPR for MD and MP cathe-
ters remained unchanged at 83.2  3.1 and 77.1  4.8%, respectively. After subsequent switch
to insulin-free perfusate, tissue glucose concentration and TPR increased slowly and reattained
preinsulin delivery levels by the end of the experiments.
CONCLUSIONS — The results show the attainment of a stable TPR value at the site of
insulin administration, thus indicating that insulin delivery and glucose sensing may be per-
formed simultaneously at the same adipose tissue site.
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W
hen insulin is secreted from the
pancreas,theresultingriseinthe
blood insulin level acts to lower
the blood glucose concentration by both
suppressing glucose production in the
liver and enhancing glucose uptake in in-
sulin-sensitivetissues(mainlymuscleand
adipose tissue) (1). Studies (2,3) investi-
gating insulin’s effect on glucose uptake
in isolated muscle and fat cells have
shown that the cellular response to in-
creasinginsulinconcentrationisacontin-
uous increase in glucose uptake until a
maximal response is reached. Further in-
creases in the prevailing insulin concen-
trations beyond this threshold level does
not further increase glucose uptake.
Similar saturation-type concentration-
response characteristics were found for
insulin-stimulated arteriovenous glucose
difference, blood ﬂow, and glucose up-
take(4,5)intheforearmandlegaswellas
for insulin-stimulated whole-body glu-
cose uptake (1,4,5). In these in vivo stud-
ies, the maximal response to insulin in
healthy humans was observed to occur at
a blood plasma concentration of 300–
1,000 U/ml (1,4,5). Most notably, this
maximally effective insulin level is
100,000 times lower than the insulin
concentration in preparations currently
used in the replacement therapy of dia-
betic patients (100 units/ml) (6). Thus,
given the observed saturation-type rela-
tionship between insulin concentration
and insulin’s effect on arteriovenous glu-
cose difference, blood ﬂow, and glucose
uptake in human peripheral tissues, we
reasoned that a similar saturation-type
concentration-response characteristic for
theinsulin-stimulateddifferencebetween
arterial blood glucose levels and intersti-
tial ﬂuid (ISF) glucose concentrations
might exist in these tissues (online
appendix Fig. 1 [available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1531/DC1]). An interstitial infusion
of insulin into adipose tissue at rates used
inthereplacementtherapyofdiabeticpa-
tients might therefore evoke insulin con-
centrations at the infusion site that are
much higher than the maximally effective
insulin level of this tissue and, in turn,
might ensure an essentially maximal and
stableblood-to-ISFglucoseconcentration
gradient in the tissue at this infusion site.
Ifthiswerethecase,thendespitethepres-
ence of variable insulin delivery rates,
reliable estimation of blood glucose con-
centrations from glucose concentrations
measuredintheISFattheinsulindelivery
site would be possible.
The present study was undertaken
to investigate this possibility in the sub-
cutaneousadiposetissueofhealthysub-
jects. Microperfusion and microdialysis
techniques were utilized to perform
glucose sampling and simultaneous in-
sulin delivery at the same adipose tissue
site. Using these techniques, ISF glu-
cose samples from the site of insulin de-
livery were obtained in the presence of
variable insulin delivery rates. The ob-
served ISF glucose levels were then
compared with plasma glucose concen-
trations as well as to glucose levels in
ISF samples from insulin-unexposed
adipose tissue.
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METHODS— The study was con-
ducted in ﬁve healthy male adult volun-
teers.Theageofthesubjectswas29.84.0
years (range 19–44) and the BMI was
23.0  0.9 kg/m
2 (20.7–26.0). Written in-
formed consent was obtained after the pur-
pose,nature,andpotentialrisksofthestudy
were explained to the subjects. The study
was approved by the ethics committee of
the Medical University of Graz.
Inthemorningafteranovernightfast,
study subjects were admitted to the clin-
ical research center. At 7:30 A.M., an in-
travenouscatheterwasplacedintoanarm
vein for glucose infusion. Another cathe-
ter was inserted into a vein of the con-
tralateral hand for blood sampling. The
forearm with the sampling catheter was
then placed in a thermoregulated box
(55°C) to ensure arterialization of the
venous samples. Subsequently, a 24-
gauge microperfusion (MP) catheter
(7,8) and a microdialysis (MD) catheter
(CMA60, modiﬁed as described below;
CMA/Microdialysis, Solna, Sweden)
were inserted into the periumbilical
subcutaneous adipose tissue, and peri-
staltic pumps (Minipuls 3; Gilson, Villi-
ers-le-Bel, France) were attached to the
inﬂow and outﬂow tubing of each cathe-
ter (Fig. 1). Both catheters were then se-
quentially perfused with an insulin-free
solution (5% mannitol; Fresenius Kabi,
Graz, Austria) for 2 h, a standard human
insulin preparation (100 units/ml Ac-
trapid; Novo Nordisk, Bagsvaerd, Den-
mark) for 6 h, and, again, an insulin-free
solution (5% mannitol) for 2 h. During
the 6-h insulin perfusion period, the in-
sulin delivered to the tissue by the MP
catheter was at a rate of 0.33 units/h
over the ﬁrst 2 h, 0.66 units/h over the
subsequent 2 h, and 1.00 units/h over
theﬁnal2h.Similarinsulindeliveryrates,
but in reverse chronological order, were
administered via the MD catheters. As the
outﬂow rates of the two catheters were
maintained at a constant value (0.45
l/min) throughout the experiment, the
insulin delivery rate of each catheter was
adjusted by simply adjusting the inﬂow
rate of the catheter (dual-pump operation
mode) (9) (Fig. 1). During the experi-
ment, catheter efﬂuents were continu-
ously collected in 30-min fractions in
vials(Microvial;CMA/Microdialysis)kept
on ice and covered to avoid ﬂuid evapo-
ration. In parallel, glucose concentrations
in blood plasma were measured fre-
quently (i.e., every 5–30 min), and, to
preventafallinthebloodglucoseconcen-
tration during and after the subcutaneous
insulindeliveryperiod,glucose(0.1g/ml;
Fresenius Kabi) was intravenously in-
fused at a variable rate.
Microperfusion, microdialysis, and
analytical procedures
MP and MD catheters applied were of
concentric design with a cylindrical inner
and outer tube (Fig. 1B and C). The outer
tube of the MP catheter (7,8) consisted of
a conventional, intravenous 24-G can-
nula (shaft length: 19 mm, Neoﬂon; Bec-
ton Dickinson, Helsingborg, Sweden) in
which 27 perforations (each 0.3 mm in
diameter) were formed in the cannula
wall using an Excimer laser (LZH, Han-
nover, Germany). Two 750-mm lengths
ofTygontubing(outerdiameter:2.0mm,
inner diameter: 0.19 mm; Cole-Parmer,
Vernon Hills, IL) were used to connect
catheter inlet and outlet with perfusate
reservoir and sampling vial, respectively.
In the case of the MD catheter (CMA60),
part of the outer tube was made from a
polyamide membrane with a molecular
weight cutoff of 20 kDa (membrane
length: 30 mm, pore sizes: 1 m). To
operate MD catheters in the dual pump
mode(Fig.1),theoriginalinﬂowandout-
ﬂowtubingofthecatheterswerereplaced
by two 750-mm lengths of Tygon tubing.
In addition, to increase the insulin deliv-
ery efﬁciency of MD catheters, a ﬂuid
communication between the distal inner
tubeendandtheoutersurfaceofthecath-
Figure 1—Schematic of the experimental set-up for the assessment of insulin’s effect on the
glucose concentration at the tissue site of insulin delivery. A: A microperfusion (MP) and a
microdialysis (MD) catheter were inserted into subcutaneous adipose tissue of healthy subjects
(n5).Bothcatheterswereperfusedsequentiallywithaninsulin-freesolution(mannitol)for2h,
astandardhumaninsulinpreparation(100units/ml,Actrapid)for6h,and,again,aninsulin-free
solution (mannitol) for 2 h. Perfusion of each catheter was accomplished by applying two peri-
staltic pumps, with one pump (1, 1) attached to the inﬂow tubing and another (2, 2)t ot h e
outﬂow tubing (dual-pump operation mode [9]). B and C: The perfusate streamed through the
inﬂow tubing and the inner cannula to the tip of the catheter and then entered the space between
inner and outer cannula of the catheter (bold arrows). By operating the inﬂow pump at a higher
speedthantheoutﬂowpump,afractionoftheperfusateenteringthespacebetweeninnerandouter
cannula was forced to ﬂow through the perforations and membrane pores of the MP and MD
catheter, respectively, to the surrounding tissue (tissue-directed ﬂows indicated by thin straight
arrows). The magnitude of this ﬂow fraction and, thus, the amount of perfusate solutes (e.g.,
insulin)convectivelytransportedtothetissuewascontrolledbycontrollingthedifferencebetween
the inﬂow and outﬂow rates of the catheter. In parallel to this convective tissue-directed solute
transport,diffusivebidirectionalsolutetransporttookplaceacrosstheperforationsandmembrane
pores of the MP and MD catheter, respectively (wavy arrows), thereby causing ISF solutes (e.g.,
glucose) to enter the ﬂuid fraction that ﬂowed in the space between inner and outer cannula of the
catheter (bold striped arrows). Along with the permeated ISF solutes, this ﬂuid fraction was
pumped continuously through catheter outlet and outﬂow tubing to the collecting vial. The efﬁ-
ciency by which glucose was transported via diffusion from the ISF of the tissue into the catheter
(glucose recovery) was measured by applying the ionic reference technique (7,8).
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foration into the catheter tip using a 30-G
syringeneedle(pointlength:1.2mm;Mi-
crolance, Becton Dickinson, Drogheda,
Ireland). To monitor the outﬂow rate of
the MP and MD catheters and to deter-
mine the exact sampled efﬂuent volume,
the sample vials were weighed before and
after sample collection. The efﬂuent sam-
pling delay time introduced by the dead
space volume of the catheter outﬂow tub-
ingwastakenintoaccountwhenthesam-
ple collection was begun.
Plasma glucose concentrations were
measured at the bedside using a Beckman
Glucose Analyzer II (Beckman Instru-
ments,Fullerton,CA)withacoefﬁcientof
variation (CV) of 2%. The glucose con-
centrations in catheter efﬂuents were de-
termined using an automated CMA600
analyzer (CMA/Microdialysis) with a
within-run CV of 2%. Separate in vitro
experiments have shown that preserva-
tives contained in the regular human in-
sulin solution used to perfuse the
catheters (Actrapid) do not compromise
the accuracy of the CMA600 glucose an-
alyzer. The conductivities in the plasma,
perfusate, and catheter efﬂuent samples
were measured using a contactless con-
ductivity detector (TraceDec; I.S.T.,
Strasshof,Austria).Theelectricalconduc-
tivity was determined with a within-run
CV of 1%.
Data analysis
The ISF glucose concentration was calcu-
lated (7,8) as the glucose concentration
in the catheter efﬂuent sample divided by
the glucose recovery of the catheter (R).
Therecoverywasdeterminedforeachsam-
pling period as R  (Cout  Cin)/(Cpl 
Cin), where Cin, Cout, and Cpl are the
measured electrical conductivity in the per-
fusate, the efﬂuent sample, and the corre-
sponding plasma sample, respectively.
Application of this technique (ionic refer-
ence technique) (7,8) was possible be-
cause the electrical conductivity in the
used catheter perfusates was either negli-
gible (mannitol) or low compared with
thatinbloodplasma(Actrapid:1.7%of
average Cpl). To facilitate comparison of
glucose time courses observed in the tis-
sue ISF with those determined in the
blood plasma, we calibrated the MP-
derived and MD-derived ISF glucose val-
ues against the mean plasma glucose
concentration observed during the 2-h
baseline period (basal calibration). These
glucose values (termed tissue glucose
concentrations) and the corresponding
plasma glucose levels were then used to
calculatethetimecoursesofthetissue-to-
plasma glucose ratio (TPR). The differ-
ences of mean glucose and TPR results
were examined by one-factor repeated-
measures ANOVA. If signiﬁcance was
achieved, post hoc comparison of means
with Dunnett’s test was performed. A P
value0.05wasconsideredtoindicatesta-
tistical signiﬁcance. Normality of data were
assessed using normal probability plots.
Data are presented as means  SE. Data
analysis was performed using MATLAB
(MathWorks, Natick, MA) and SPSS (SPSS,
Chicago, IL) software packages.
RESULTS
Glucose dynamics at the site of
subcutaneous insulin administration
Figure 2A shows the time courses of the
glucose concentration in arterialized
blood plasma and in the tissue surround-
ing the MP and MD catheters. Com-
mencement of insulin delivery with the
MDandMPcathetersinducedafallinthe
tissue glucose concentration for 60 min
(P  0.05). However, during the rest of
the6-hperiodofvariableinsulindelivery,
the tissue glucose concentration paral-
leled the glucose concentration observed
in plasma, thereby indicating that insu-
lin’s effect on the tissue glucose concen-
tration saturated within 60 min after the
start of insulin administration. After
switching back from insulin to mannitol
perfusates, tissue glucose concentration
increased slowly and reattained plasma
glucose levels at the end of the experi-
ments (Fig. 2A).
Figures 2B and C depict the TPR for
the MD and MP catheters as a function of
time. As can be seen, during the ﬁrst 60
min of insulin delivery, the TPR declined
to a level of 83.8  3.6 and 78.5  5.0%
for MD and MP catheters, respectively,
andthenremainedattheselevelsuntilthe
end of the 6-h period of variable insulin
delivery. During the ﬁnal5ho ft h einsu-
lin delivery period, the TPR levels for MD
and MP catheters averaged 83.2  3.1
and 77.1  4.8%, respectively.
Taken together, the temporal pattern
of change in tissue and plasma glucose
and TPR values suggests that within 60
min after exposing adipose tissue to a
standard 100 units/ml insulin prepara-
tion, insulin’s effect on the tissue glucose
concentration saturates and a stable ratio
between the tissue and plasma glucose
concentration is attained.
Glucose recoveries and insulin
infusion rates
Attheusedoutﬂowrateof0.47l/min,
the transport efﬁciency (recovery) of glu-
cose for the MP catheter was found to be
25.15.4%duringtheﬁrst2hofinsulin
delivery and remained unchanged during
thesubsequent2handﬁnal2hofinsulin
delivery (24.6  4.4 and 24.8  4.9%,
respectively; P  0.93, one-factor repeat-
ed-measures ANOVA). Similarly, recov-
ery for the MD catheter was 96.8  1.2%
during the ﬁrst2ho finsulin delivery and
remained at this level during the subse-
quent 2 h (98.0  1.3%) and ﬁnal 2 h
(98.1  1.3%) of insulin delivery (P 
0.20, one-factor repeated-measures
ANOVA). The lower glucose recovery
for MP catheters compared with MD
catheters may be mainly attributable to
the different size of the exchange area of
the applied catheters (MP perforations
distributed over an 11-mm shaft length
versus MD membrane length of 30
mm). Figure 2B and C show the average
time course of the total insulin delivery
rate (i.e., the sum of the convective and
diffusiveportionsoftheinsulindelivery
rates) for the MD and MP catheters (see
also online appendix supplementary
methods).
Glucose infusion rates
The time course of the intravenous glu-
cose infusion rate is shown in online
appendix Fig. 2. As can be seen, the
glucose infusion rate needed to main-
tain euglycemia gradually increased
duringthesecondhalfofthe6-hinsulin
delivery period and reached a peak
value of 1.75  0.31 mg   kg
1   min
1
1 h after termination of insulin delivery.
Glucose infusion was required until the
end of the experiments.
CONCLUSIONS — The present in-
vestigation was undertaken to assess
insulin’s effect on the tissue glucose con-
centration at the site of subcutaneous in-
sulin administration. For this reason, we
subcutaneously administered insulin at
variable rates and simultaneously sam-
pled ISF glucose directly from the admin-
istration site. To carry out ISF glucose
sampling and simultaneous insulin ad-
ministration at the same adipose tissue
site, we utilized MP and MD catheters to-
gether with standard insulin preparations
as catheter perfusates and used two peri-
staltic pumps to operate each catheter
(Fig. 1). This technique of catheter oper-
ation allowed the withdrawal of ISF at a
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adjustment of the insulin delivery rate
during the experiments.
When insulin delivery to the adipose
tissue of the healthy humans was started
at basal rates similar to those used in the
replacement therapy of diabetic patients,
there was an initial delay of 60 min be-
fore the effect of insulin on the tissue-to-
blood glucose concentration gradient at
this delivery site reached its maximum
(Fig. 2). This observed delay in insulin
action (activation time) may be a reﬂec-
tion of the time required for the convec-
tional and diffusional transport of insulin
from the catheter to the surface of the in-
sulin-sensitive fat cells surrounding the
catheter as well as for the subsequent re-
cruitment and activation of glucose trans-
port proteins stimulating cell glucose
uptake(10).Afterthisactivationtime,de-
spite changes in the insulin delivery rates,
the tissue–to–blood glucose concentra-
tion gradient remained stable, thereby
supporting our hypothesis that insulin’s
effect on the tissue glucose concentration
attheinsulindeliverysiteissaturatedand
attains steady-state values. This steady-
state condition in insulin action at the in-
sulin delivery site in turn allowed us to
reliably estimate blood glucose concen-
trations from glucose concentrations
measuredintheISFofthistissuesite(11).
Afterswitchingbackfrominsulintoman-
nitol perfusates, the tissue glucose con-
centration and the tissue–to–blood
glucose concentration gradient increased
slowly and reattained preinsulin delivery
levels by the end of the 2-h mannitol per-
fusion period (Fig. 2), thereby indicating
that insulin’s effect on the tissue glucose
concentration vanished within 2 h after
termination of the insulin delivery. Over-
all, the observed activation and deactiva-
tion kinetics of insulin action on the
tissue–to–blood glucose concentration
gradient in adipose tissue are compatible
with previous ﬁndings in humans show-
ing similar activation and deactivation ki-
netics of insulin’s action on the forearm
(12), leg (4), and peripheral (13) glucose
uptake.
Conclusions in the present study dif-
ferfromtherecentstudyofHermanideset
al. (14), who reported no inﬂuence of in-
sulin on the glucose concentration in the
adipose tissue located near the insulin in-
fusion site. The disparity between our re-
sults and those of Hermanides et al. may
beattributabletothedifferentexperimen-
tal procedure used to assess the effect of
insulinonthetissueglucoseattheinsulin
administration site. Whereas the MP and
MD catheters used in the present study
functioned simultaneously as insulin de-
livery and ISF sampling instruments (sin-
gle-port approaches), Hermanides et al.
(14)usedadual-portapproachconsisting
Figure2—Glucosedynamicsatthesubcutaneoustissuesiteofinsulindelivery.A:Averagetimecourse
(n  5, means  SE) of plasma glucose concentration (F) as well as tissue glucose concentration
determined with MD (‚) and MP (ƒ) catheters. *P  0.05 tissue glucose vs. corresponding plasma
glucose values, one-factor repeated-measures ANOVA, and Dunnett’s post hoc test. B and C: Average
timecourse(n5,meansSE)oftheTPRobtainedwithMD(Œ)andMP( )catheters.*P0.05;
**P  0.01 vs. the ﬁrst basal TPR value, one-factor repeated-measures ANOVA (Huynh-Feldt cor-
rected), and Dunnett’s post hoc test. Panels also show the average time course (n5, means SE) of the
insulin delivery rates (bars) of the MD (B) and MP (C) catheters.
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sion catheter and an MD catheter, which
hadamembranelengthof25mm(14,15)
and which was inserted in subcutaneous
tissue at a closest mean distance of 9  2
mm from the infusion catheter. Thus, in
contrasttoourstudyinwhichISFglucose
was withdrawn from the insulin-exposed
tissue layer surrounding the MD and MP
catheter, Hermanides et al. (14) per-
formed ISF glucose sampling from tissue
regions that were at considerable dis-
tances from the insulin administration
site. A previous study by Linde and Philip
(16), using radiography of the radioactiv-
ity distribution of subcutaneously in-
jected
125I-insulin, indicated that when a
bolus amount of 0.25 ml of a 40 unit/ml
insulinsolution(10units)isadministered
subcutaneously, the maximal volume of
distribution of the administered insulin
may have an average cross-sectional area
of 170 mm
2 or an average radius of 7
mm (when a near-spherical shape is as-
sumed) (17). Furthermore, our recent
study in diabetic subjects (11), using MP
catheters for insulin delivery and simulta-
neous glucose sampling, showed that a
subcutaneous administration of a bolus
amount of 0.08 ml of a 100 unit/ml in-
sulin solution (8 units) is causing a di-
lution of the ISF at the insulin delivery
site, thereby decreasing the glucose con-
centration around the insulin delivery
catheterduringandshortlyafterthebolus
delivery period. In comparison, in the
study of Hermanides et al. (14), a bolus
amount of 0.11 ml of a 100 unit/ml in-
sulin solution (11 units) was adminis-
tered. Apparently, no decrease in the
efﬂuent glucose during the bolus admin-
istrations and, thus, no dilution effect of
the insulin solvent were observed. There-
fore, a possible reason for not observing a
signiﬁcant effect of insulin and/or insulin
solvent on the local tissue glucose con-
centration in their study may be that, due
to the considerable length of the microdi-
alysis membrane used (25 mm), the
whole or most parts of the glucose-
exchanging membrane, especially the
membrane part near the catheter outlet,
may not have been positioned in the in-
sulin-exposed tissue layer surrounding
the insulin infusion catheter. There have
been other studies evaluating the effect of
insulin on the glucose concentration in
humanadiposetissuebyusingeithercon-
tinuousglucosesensors(18,19)ormicro-
dialysis-based glucose sensing (19–21).
However, whereas we and Hermanides et
al. (14) assessed the effect of supraphysi-
ological insulin levels (i.e., 100 units/ml)
on the adipose tissue glucose concentra-
tion, these studies evaluated the effect of
physiological insulin levels (150
U/ml) on this glucose concentration.
Furthermore, in contrast to the study of
Hermanides et al. (14) and our study,
where insulin was locally introduced into
the ISF of subcutaneous adipose tissue,
these studies invariably increased the in-
sulin levels in the central circulation by
intravenous insulin infusions (18–21)
and/or by enhancing endogenous insulin
secretion using intravenous glucose infu-
sions (18,19). The results of these studies
indicated that physiological changes in
the insulin levels affect (19,21) or do not
affect (18,20) the ISF-to-plasma gradient
in human adipose tissue. The divergent
ﬁndings may be partially attributable to
technical and procedural differences in
the performance of the studies (18).
Besides the effect of insulin on the fat
cell glucose uptake, an additional mecha-
nism potentially inﬂuencing the glucose
concentration at the site of insulin deliv-
ery may be the local dilution of the ISF by
theinsulinsolvent.Wereasonedthatifan
increase in the perfusate ﬂow fraction di-
rected to the tissue (Fig. 1, thin straight
arrows) is causing a dilution of the ISF
surrounding the catheter, then there will
beadecreaseintheefﬁciencyofexchange
of solutes between the ISF and the perfu-
sates of the two catheters. We found that
changes in the tissue-directed ﬂow rates
did not cause changes in the exchange ef-
ﬁciency (recovery) of the two catheters,
thereby suggesting that insulin solvent
delivery at basal rates is not diluting the
ISF in the tissue surrounding the cathe-
ters. This observation is in agreement
with the results of our recent study in
diabetic subjects (11), in which after
changes in the basal delivery rates, no
changes in the catheter recovery were ob-
served. The relatively high blood ﬂow per
unit adipose tissue weight (20–30 l  
min
1   g
1) (22) compared with the
amountofinsulinsolutioninfusedduring
basal delivery (0.1–0.2 l/min) may be
the likely reason for not observing a local
dilution of the ISF when basal insulin is
delivered.
Our present and recent study (11)
may also provide the basis for the pursuit
of a principal concept to the design of a
single-port treatment system. This con-
cept involves the integration of a contin-
uous glucose sensor directly onto the
shaft wall of an insulin infusion catheter.
When connected to an insulin pump, the
system may then permit simultaneous in-
sulin infusion and glucose sensing. Avail-
able information on solute transport in
ISF surrounding infusion catheters
(which is governed by a combination of
convection, diffusion, and tissue clear-
ance)(17,23,24)maybeusedtoguidethe
exact placement of the glucose sensor
onto the shaft of an insulin infusion cath-
eter. For example, when a typical bolus
amount of 0.1–0.2 ml (10–20 units) of a
standard insulin solution is administered
through a conventional infusion catheter
(diameter: 0.5 mm; shaft length: 10
mm), there may be a signiﬁcant backﬂow
of infusate from the catheter tip along the
cathetershaft(24)towardtheskin,sothat
the initial area of distribution of infused
insulin (initial depot volume) (17,23)
may correspond to a cylindrical tissue
layer surrounding the catheter shaft (24)
and having a width of a few millimeters
(17). Shortly after bolus administration,
the relative rates of diffusion and clear-
ance may then produce ﬁrst an expansion
of the insulin-exposed tissue layer about
the catheter shaft to a width of several
millimeters (e.g., 7 mm) (16) and, as
soon as clearance prevails, a decrease of
the size of this layer, so that 6–10 h after
bolus administration, all the insulin is
cleared from the tissue site of insulin ad-
ministration (17,21). Furthermore, in the
case of insulin delivery at basal rates
(0.01 ml/h  1 unit/h, usually ad-
ministered as microboluses with 0.025–
0.1unitsperpumpstroke)(25),backﬂow
distances may be shorter and hence the
volume of insulin-exposed tissue about
the catheter shaft may be smaller than af-
ter bolus administrations (24). Therefore,
when a basal-bolus insulin regimen is ap-
plied, the best placement location of a
continuousglucosesensoronthecatheter
shaft may be close to the catheter tip be-
cause at this site the tissue surrounding
the sensor may be permanently exposed
to insulin. In the case of suspension
of the insulin pump treatment, a recali-
bration of the glucose sensor may be
required when the length of pump sus-
pension exceeds the deactivation time
of insulin action. The deactivation time,
however, may largely depend on the ac-
tual insulin depot size at the delivery
site, which can be very high after bolus
administrations or lower after pro-
longed basal insulin delivery (two to
ﬁve times the hourly infusion rates)
(25).
In summary, our results show that
within 60 min after exposing adipose tis-
Lindpointner and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 4, APRIL 2010 837sue to a standard 100 units/ml insulin
preparation, insulin’s effect on the tissue
glucose concentration saturates and a sta-
ble ratio between the tissue and plasma
glucoseconcentrationisattained,thusin-
dicating that insulin delivery and glucose
sensing may be performed simulta-
neously at the same adipose tissue site via
a single tissue catheter. This single-port
treatment approach may hold great
promise to simplify and improve glucose
management in diabetes.
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